CEO John Jacobs resigns; CMO Jeffrey Dayno named Interim CEO; Jeff Aronin becomes Executive Chairman

Harmony Biosciences Holdings, Inc.

CEO John C. Jacobs resigns effective Jan 20, 2023 to pursue another opportunity; no disagreement with Company.
Jeffrey M. Dayno, current CMO, appointed Interim CEO effective Jan 6, 2023; will remain CMO.
Founder and Board Chairman Jeffrey S. Aronin appointed Executive Chairman to provide oversight during transition.
Board expresses confidence in underlying business and strategic execution.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Jeffrey M. Dayno

Interim Chief Executive Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-01-06
Filed: January 6, 2023, 6:59 PM ET

On January 6, 2023, the Board appointed Dr. Jeffrey M. Dayno, the Company’s current Chief Medical Officer, as the Company’s Interim Chief Executive Officer, effective January 6, 2023.

Departed

John C. Jacobs

President and Chief Executive Officer

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-01-20
Successor: Jeffrey M. Dayno
Filed: January 6, 2023, 6:59 PM ET

On January 6, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) announced that John C. Jacobs is resigning as President and Chief Executive Officer of the Company.

Appointed

Jeffrey S. Aronin

Executive Chairman

HRMY · Harmony Biosciences Holdings, Inc.

Effective: 2023-01-06
Filed: January 6, 2023, 6:59 PM ET

On January 6, 2023, in connection with Mr. Jacobs’ resignation from the Board and to provide additional support and oversight during this transition period, the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey M. Dayno was appointed as Interim Chief Executive Officer at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

On January 6, 2023, the Board appointed Dr. Jeffrey M. Dayno, the Company’s current Chief Medical Officer, as the Company’s Interim Chief Executive Officer, effective January 6, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John C. Jacobs resigned as President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..

Action: resigned
Role: President and Chief Executive Officer

Exact text from the filing

On January 6, 2023, Harmony Biosciences Holdings, Inc. (the “Company”) announced that John C. Jacobs is resigning as President and Chief Executive Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..

Action: appointed
Role: Executive Chairman

Exact text from the filing

On January 6, 2023, in connection with Mr. Jacobs’ resignation from the Board and to provide additional support and oversight during this transition period, the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.

View on SEC.gov

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-001895

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.